Although patients with MS or these psychiatric disorders were excluded from this study, plasma CLDN-5 levels should be investigated in patients with AD and other central nervous system-related diseases in order to understand the clinical utility of plasma CLDN-5 levels. This evidence concerns the gene CLDN5 and myeloid sarcoma.